Diagnostic Substances
(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss
AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus Estimate for the reported quarter was a loss of $1.08. The lower loss in...
3Mar2010 | vitalstocks | 0 comments | Continued(MYGN) Myriad Surpasses Consensus Estimates
Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued...
4Feb2010 | vitalstocks | 0 comments | Continued(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates
Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents. Sales Total revenues in the third quarter increased 15% year over year to $31.0 million,...
1Feb2010 | vitalstocks | 0 comments | Continued(SRDX) SurModics Earnings Report Beats Expectations
SurModics (SRDX) reported first quarter fiscal 2010 earnings per share (EPS) of 11 cents, down from $1.53 in the year ago period. However, after adjustments, the EPS of 24 cents surpassed the Zacks Consensus Estimate by 5 cents. The company reported revenues of $17.4 million,...
29Jan2010 | vitalstocks | 0 comments | Continued(VIVO) Meridian Bioscience Misses Expectations by a Penny
Recently, Meridian Bioscience Inc. (VIVO) reported results for the first quarter of fiscal 2010. The company earned 22 cents per share in the quarter which fell short of the Zacks Consensus Estimate by a penny. Meridian Bioscience earned 20 cents per share in the year-ago quarter. Net...
23Jan2010 | vitalstocks | 0 comments | Continued(ABAX) Abaxis Receives FDA Approval
Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by healthcare professionals in conjunction with Abaxis’ Piccolo Xpress...
23Jan2010 | vitalstocks | 0 comments | Continued(AMAG) AMAG Pharmaceuticals Guides on Feraheme
Recently, AMAG Pharmaceuticals Inc. (AMAG) stated that it expects net revenues between $12 and $13 million from its lead anti-anemia injectable product Feraheme for the fourth quarter of fiscal 2009 (ended December 31). AMAG had launched the Feraheme (ferumoxytol) injection in...
12Jan2010 | vitalstocks | 0 comments | Continued(BLUD) Immucor Beats Earnings Estimates
Immucor (BLUD) announced second quarter 2010 earnings per share of 28 cents, which was better than the Zacks Consensus Estimate of 26 cents and the year-ago quarter’s 24 cents. Net income for the quarter was $19.7 million, compared with $17.3 million for the same quarter last...
8Jan2010 | vitalstocks | 0 comments | Continued(ABAX) Abaxis Launches New Bird Flu Test Product
Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed test for Avian Influenza Type A nucleoprotein antigen in chickens,...
29Dec2009 | vitalstocks | 0 comments | Continued(NEOG) Neogen Beats Earnings Expectations by a Penny
Neogen Corp. (NEOG) recently posted fiscal second quarter results. The company’s GAAP net income grew 18% to $4.6 million, compared to $3.9 million in the year-ago period. Adjusting for a 3-for-2 stock split effective Dec 15, earnings per share came in at 20 cents per share,...
22Dec2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Upgraded to Neutral
We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking...
17Dec2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bear of the Day
Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July...
16Nov2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny
Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97...
8Nov2009 | vitalstocks | 0 comments | Continued(SRDX) SurModics Misses Earnings Estimates
SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year ago period. In addition to quarterly results, SurModics came out with fiscal...
7Nov2009 | vitalstocks | 0 comments | Continued(ABAX) Abaxis Earnings Report Lags Consensus Estimates
Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents. Total revenues for the reported quarter were $30.3 million, logging a growth of 9% year over year....
28Oct2009 | vitalstocks | 0 comments | Continued(SRDX) Surmodics Inks Licensing Deal With Roche
On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device...
9Oct2009 | vitalstocks | 0 comments | Continued(BLUD) Immucor Beats Estimates – Reaffirmed Fiscal 2010 Revenue and Earnings Guidance
Recently, Immucor (BLUD) announced its first quarter (ending August 2009) 2010 earnings of 30 cents, which was better than the Zacks Consensus Estimate of 25 cents and the year ago quarter’s earnings of 28 cents. Net income in the quarter was $21.3 million, compared with $20.0...
6Oct2009 | vitalstocks | 0 comments | Continued(ISTA) ISTA Pharmaceuticals Eye Drug Gets FDA Approval
Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a...
9Sep2009 | vitalstocks | 0 comments | Continued(ISTA) ISTA Pharmaceuticals’s Eye Drug Shows Success
ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye. ISTA...
27Aug2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate
Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular...
26Aug2009 | vitalstocks | 0 comments | Continued(AVGN) Avigen to Be Acquired
On Friday, Avigen Inc. (AVGN) announced that it will be purchased by MediciNova, Inc. (MNOV) for $1.24 per share in either cash or secured convertible notes. The deal has been valued at about $37 million. Approximately $1.19 of the consideration is scheduled be paid to Avigen...
25Aug2009 | vitalstocks | 0 comments | Continued(MYGN) Biotech Industry – Zacks Analyst Interviews
OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over...
1Jun2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank Buy
Myriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on Feb 3 and announced a 2-for-1 stock split on Feb 24. Second-Quarter Results Much of Myriad’s recent price strength is built upon the company’s solid second-quarter...
16Mar2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basis
Myriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts are responding with sharp increases in earnings estimates. Company Description Myriad Genetics uses gene-based medicine to develop therapeutic and molecular diagnostic products....
10Feb2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Revenue increased 53% from last year
Myriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great quarter in early November. Analysts are bullish on the company, with the next-year estimate projecting 60% earnings growth. Company Description Myriad Genetics is a healthcare...
14Jan2009 | Shawn | 0 comments | Continued(BLUD) Immucor – third consecutive earnings surprise
Immucor Inc.(BLUD) recently reported a company record for net income in a quarter and completed an acquisition. Earnings are showing solid growth for next year and are traded at a fair value. Company Description Immucor is an international in vitro diagnostic company dedicated...
26Dec2008 | Shawn | 0 comments | Continued